Conversion DisorderNCT00971360
Cytokine Levels in Conversion Disorder
An observational study of Conversion Disorder, run by Trakya University at 1 site in Turkey (Türkiye).
Trial summary
The aim of this study is whether the proinflammatory cytokine levels in patients with conversion disorder is increased or not changed in the acute phase and subacute - chronic periode, compared with controls. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Conversion Disorder
- What is being tested?
- conversion disorder
- How many people
- 30 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- Sep 2009to Sep 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: primary care clinic
Who may be able to join
- Clinical diagnosis of Alzheimer's Disease
Who cannot join
- Autoimmune disease
- Neurological disease
- Any organic disorder that could possibly affect proinflammatory cytokines
- Pregnancy
- Any drug usage within 2 weeks
- Any active or passive immunization within 6 months
Show all 9Show fewer
- Any other DSM-IV axis I psychiatric disorder
- Mental retardation
- Developmental disorder of childhood
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Trakya University Faculty of Medicine; Department of Psychiatry
Edirne, 22030
About this study
Official title: Proinflammatory Cytokine Levels in Patients With Conversion Disorder
The aim of this study is whether the proinflammatory cytokine levels in patients with conversion disorder is increased or not changed in the acute phase and subacute - chronic periode, compared with controls.
- Conditions
- Conversion Disorder
- Being tested
- conversion disorder
- Keywords
- conversion, cytokine, inflammation
- Medical subject headings
- Conversion Disorder, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
conversion disorderOther
Proinflammatory cytokine levels in conversion disorder
| Study group | Role | What they receive |
|---|---|---|
| Conversion disorder | Not described Receives: Other: conversion disorder | |
| Healthy control | Not described Receives: Other: conversion disorder |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2009 (estimated)
- Study startSep 2009
- Primary completionSep 2010
- Study completionSep 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Conversion DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Trakya University
- Sponsor type
- University, hospital or other
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00971360
- Sponsor's protocol ID
- TUTFEK 2009/173
- Status last verified
- Sep 2009
- First submitted
- 2 Sep 2009
- Last updated
- 20 Oct 2010
- Results posted
- No
- Data monitoring committee
- No
Publications
Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res. 2001 Dec 31;105(3):165-74. doi: 10.1016/s0165-1781(01)00338-9.
PubMed 11814536Ziemssen T, Kern S. Psychoneuroimmunology--cross-talk between the immune and nervous systems. J Neurol. 2007 May;254 Suppl 2:II8-11. doi: 10.1007/s00415-007-2003-8.
PubMed 17503136Dantzer R. Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology. 2005 Nov;30(10):947-52. doi: 10.1016/j.psyneuen.2005.03.011.
PubMed 15949897
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Proinflammatory Cytokine Levels in Patients With Conversion Disorder
- ClinicalTrials.gov ID
- NCT00971360
- Acronym / sponsor ID
- TUTFEK 2009/173
- Conditions
- Conversion Disorder
- Keywords
- conversion, cytokine, inflammation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Trakya UniversityUniversity, hospital or other
- Study start
- Sep 2009
- Primary completion
- Sep 2010 (actual)
- Study completion
- Sep 2010 (actual)
- First posted
- 3 Sep 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is whether the proinflammatory cytokine levels in patients with conversion disorder is increased or not changed in the acute phase and subacute - chronic periode, compared with controls.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conversion disorder | – | Other: conversion disorder |
| Healthy control | – | Other: conversion disorder |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- primary care clinic
Key inclusion criteria (1 listed)
- Clinical diagnosis of Alzheimer's Disease
Key exclusion criteria (9 listed)
- Autoimmune disease
- Neurological disease
- Any organic disorder that could possibly affect proinflammatory cytokines
- Pregnancy
- Any drug usage within 2 weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| conversion disorderProinflammatory cytokine levels in conversion disorder | Other | Conversion disorder, Healthy control |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2010.
- Background: PubMed 11814536Rief W, Pilger F, Ihle D, Bosmans E, Egyed B, Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res. 2001 Dec 31;105(3):165-74. doi: 10.1016/s0165-1781(01)00338-9.
- Background: PubMed 17503136Ziemssen T, Kern S. Psychoneuroimmunology--cross-talk between the immune and nervous systems. J Neurol. 2007 May;254 Suppl 2:II8-11. doi: 10.1007/s00415-007-2003-8.
- Background: PubMed 15949897Dantzer R. Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology. 2005 Nov;30(10):947-52. doi: 10.1016/j.psyneuen.2005.03.011.
Related trials for Conversion Disorder
Not yet recruitingPhase 2
A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT Conversion in Stable Liver Transplant Patients
Hepatitis B Virus, Liver Transplant
Not yet recruiting
Clinical Hypnosis Versus Guided Imagery for Dissociative Symptoms in Adults
Dissociative Symptoms
Recruiting
EXercise-induced PhysioLogical Adaptations In Neurological Disorders
Epilepsy, Functional Neurological Disorder
RecruitingPhase 3
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
Gastric Cancer, Peritoneal Metastasis
RecruitingPhase 2
Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Gastric Adenocarcinoma, Stomach Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Conversion Disorder, run by Trakya University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Oct 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00971360, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2010.